NKGen Biotech, Inc.

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 3001 DAIMLER ST,, SANTA ANA, CA, 92705
Mailing Address 3001 DAIMLER ST,, SANTA ANA, CA, 92705
Phone (949) 396-6830
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024

-$44.29M
Net Income

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 5, 2026 View on SEC
8-K Current report of material events January 26, 2026 View on SEC
10-Q Quarterly financial report January 20, 2026 View on SEC
8-K Current report of material events January 16, 2026 View on SEC
8-K Current report of material events January 9, 2026 View on SEC
10-K Annual financial report October 8, 2025 View on SEC
8-K Current report of material events September 29, 2025 View on SEC
8-K Current report of material events September 24, 2025 View on SEC
8-K Current report of material events September 9, 2025 View on SEC
8-K Current report of material events July 17, 2025 View on SEC

Annual Reports

10-K October 8, 2025
  • Encouraging early results for Alzheimer’s treatment
  • Secured partnership with larger pharmaceutical company
View Analysis

Material Events

8-K Acquisition January 9, 2026
High Impact
  • NKGen Biotech, Inc. secured a significant loan of over $25.8 million from AlpineBrook Capital.
  • The loan primarily formalizes past cash advances used to acquire a majority stake in NKGen Biotech Korea Co., Ltd.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.